Literature DB >> 2227563

Radioimmunoscintigraphy of ovarian tumors using a new monoclonal antibody, SM-3.

T W Jobling1, M Granowska, K E Britton, D G Lowe, S J Mather, J Burchell, M Naeem, J H Shepherd.   

Abstract

Radioimmunoscintigraphy with SM-3 monoclonal antibody produces results similar to those obtained with 123I-labeled HMFG-2. The tumor specificity of SM-3 in vitro is not as marked as that in vivo. SM-3 is, however, much easier to produce in tissue culture and, with the availability of 99mTc labelling, has allowed radioimmunoscintigraphy to be done as an outpatient procedure. This technique has important implications for the continuing management of patients with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227563     DOI: 10.1016/0090-8258(90)90093-z

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.

Authors:  M Granowska; K E Britton; S J Mather; D G Lowe; D Ellison; J Bomanji; J Burchell; J Taylor-Papadimitriou; C R Hudson; J H Shepherd
Journal:  Eur J Nucl Med       Date:  1993-06

2.  Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe.

Authors:  T E Ind; M Granowska; K E Britton; G Morris; D G Lowe; C N Hudson; J H Shepherd
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.